The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Overcoming Early Development Challenges: Making Fit-for-Purpose Decisions Under Material, Time, Cost, and Risk Constraints
Watch this on-demand webinar to learn how to optimize your approach to early drug development and how biopharma companies and CDMOs can work together to balance speed, cost, and long-term success.
For orphan drugs, precision medicines, and other therapies where active pharmaceutical ingredients (APIs) are scarce or costly, every drug development decision matters—especially the early decisions that can make or break the long-term success of a program. This on-demand webinar explores how to design a fit-for-purpose Phase I formulation that enables rapid clinical entry while minimizing unnecessary development, API consumption, and technical risk.
Practical strategies for early drug development
In this on-demand webinar, experts discuss practical strategies for formulation selection, dosage form and presentation, stability and data requirements, platform approaches, and material efficiency. Through a risk-based framework, you’ll learn which decisions should be made early, which can remain flexible, and how biotech and pharma companies and their CDMO partners can work together to balance speed, cost, and long-term development success.
Speaker:
Christy Eatmon
Global SME, Sterile Drug Products
Pharma Services, Thermo Fisher Scientific
Christy Eatmon is Global SME for Sterile Drug Products at Thermo Fisher Scientific, bringing more than 20 years of experience in the pharmaceutical industry. She specializes in sterile filling, aseptic manufacturing, process optimization, product development, and manufacturing, with expertise spanning drug discovery through commercial production. Her experience includes scale-up, technology transfer, process development, and validation for clinical and commercial programs. Christy also has a background in small-molecule formulations for the controlled release of poorly water-soluble drugs, the characterization and surface chemistry of nanoparticle dispersions, and the scale-up of processes from the laboratory bench to clinical trial material.